COMMUNIQUÉS West-GlobeNewswire

FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair
26/03/2026
March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures , supporting treatment [2] DeviceGuide integrates with Philips Azurion [...]
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
26/03/2026
RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological [...]
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
26/03/2026
- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - - He will work with the Company’s leadership team to expand corporate collaborations to [...]
BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD
26/03/2026
BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]
Firefly Confirms Public-Private Partnership with the Department of War
26/03/2026
Firefly’s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of Company’s Commercial [...]
HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics
26/03/2026
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics NEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “ [...]
Tilray Brands Announces Partnership with Popsicle® to Launch Popsicle Adult Beverages
26/03/2026
Iconic Popsicle® Flavors Reimagined as Ready-to-Drink Hard Beverages Through New Licensing Agreement NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”, “our”, “we” or the “Company”) (Nasdaq: [...]
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
26/03/2026
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office ( [...]
Sironax Appoints Clive Wang to Board of Directors
26/03/2026
WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare [...]
Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update
26/03/2026
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its [...]
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
26/03/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s Enhanced [...]
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
26/03/2026
HOUSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for [...]
Preliminary results for the year ended 31 December 2025
26/03/2026
A year of strategic execution, strong revenue growth and positive Operating EBITDA Strong 2025 financial performance; revenues at upper end of guidance, with full year Operating EBITDA profitability achieved: Revenue [...]
Kamada Announces FDA Approval of its Plasma Collection Center in San Antonio, Texas
26/03/2026
San Antonio Center Cleared to Commence Commercial Sales of Normal Source Plasma State of the Art Facility has Annual Collection Capacity of Approximately 50,000 Liters of Plasma and an Estimated Annual Revenue [...]
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
26/03/2026
Insurance Coverage on Vivos Appliances and Treatment Now Available to a Significant Number of Nevada Patients Previously Unable to Access Coverage Concurrently, Vivos Implements Cost Reduction Initiatives Related to [...]
Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer
26/03/2026
-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth [...]
Fangzhou Inc. Appoints Healthcare Industry Veteran Wang Haijiao as Chief Executive Officer Following a Year of Record Growth and Profitability
26/03/2026
SHANGHAI, March 26, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, today announced the appointment of Mr. WANG Haijiao [...]
Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team
26/03/2026
JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents [...]
Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan
26/03/2026
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer PHILADELPHIA, March 26, 2026 (GLOBE NEWSWIRE) -- Medicus [...]

Pages